Cargando…
Elite and posttreatment controllers, two facets of HIV control
The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and v...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004771/ https://www.ncbi.nlm.nih.gov/pubmed/35938466 http://dx.doi.org/10.1097/COH.0000000000000751 |
_version_ | 1784904917624815616 |
---|---|
author | Mastrangelo, Andrea Banga, Riddhima Perreau, Matthieu |
author_facet | Mastrangelo, Andrea Banga, Riddhima Perreau, Matthieu |
author_sort | Mastrangelo, Andrea |
collection | PubMed |
description | The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and virological features underlying viral suppression in elite controllers and PTCs, and explore their possible contributions to the HIV-1 cure research. RECENT FINDINGS: HIV-1 control in elite controllers shows hallmarks of an effective antiviral response, favored by genetic background and possibly associated to residual immune activation. The immune pressure in elite controllers might select against actively transcribing intact proviruses, allowing the persistence of a small and poorly inducible reservoir. Evidence on PTCs is less abundant but preliminary data suggest that antiviral immune responses may be less pronounced. Therefore, these patients may rely on distinct mechanisms, not completely elucidated to date, suppressing HIV-1 transcription and replication. SUMMARY: PTCs and elite controllers may control HIV replication using distinct pathways, the elucidation of which may contribute to design future interventional strategies aiming to achieve a functional cure. |
format | Online Article Text |
id | pubmed-10004771 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100047712023-03-11 Elite and posttreatment controllers, two facets of HIV control Mastrangelo, Andrea Banga, Riddhima Perreau, Matthieu Curr Opin HIV AIDS CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau The quest for HIV-1 cure could take advantage of the study of rare individuals that control viral replication spontaneously (elite controllers) or after an initial course of antiretroviral therapy (posttreatment controllers, PTCs). In this review, we will compare back-to-back the immunological and virological features underlying viral suppression in elite controllers and PTCs, and explore their possible contributions to the HIV-1 cure research. RECENT FINDINGS: HIV-1 control in elite controllers shows hallmarks of an effective antiviral response, favored by genetic background and possibly associated to residual immune activation. The immune pressure in elite controllers might select against actively transcribing intact proviruses, allowing the persistence of a small and poorly inducible reservoir. Evidence on PTCs is less abundant but preliminary data suggest that antiviral immune responses may be less pronounced. Therefore, these patients may rely on distinct mechanisms, not completely elucidated to date, suppressing HIV-1 transcription and replication. SUMMARY: PTCs and elite controllers may control HIV replication using distinct pathways, the elucidation of which may contribute to design future interventional strategies aiming to achieve a functional cure. Lippincott Williams & Wilkins 2022-09 2022-07-25 /pmc/articles/PMC10004771/ /pubmed/35938466 http://dx.doi.org/10.1097/COH.0000000000000751 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau Mastrangelo, Andrea Banga, Riddhima Perreau, Matthieu Elite and posttreatment controllers, two facets of HIV control |
title | Elite and posttreatment controllers, two facets of HIV control |
title_full | Elite and posttreatment controllers, two facets of HIV control |
title_fullStr | Elite and posttreatment controllers, two facets of HIV control |
title_full_unstemmed | Elite and posttreatment controllers, two facets of HIV control |
title_short | Elite and posttreatment controllers, two facets of HIV control |
title_sort | elite and posttreatment controllers, two facets of hiv control |
topic | CONTROLLERS AND NATURAL CURES: Edited by Matthieu Perreau |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10004771/ https://www.ncbi.nlm.nih.gov/pubmed/35938466 http://dx.doi.org/10.1097/COH.0000000000000751 |
work_keys_str_mv | AT mastrangeloandrea eliteandposttreatmentcontrollerstwofacetsofhivcontrol AT bangariddhima eliteandposttreatmentcontrollerstwofacetsofhivcontrol AT perreaumatthieu eliteandposttreatmentcontrollerstwofacetsofhivcontrol |